Trend

QS Research · Michael Burry's Scion Capital analyst template · 2006

SELLAS Life Sciences Group, Inc. (SLS)

As of 2026-11-19 · 12/15 boxes filled from SEC filings and market data

Report price $14.86 (close 2026-11-19); latest close $13.66 (2026-11-20), -8.1% since the report; figures re-marked at the latest close

Conclusion: PASS

Conviction low · base case none · downside -54% · upside +41%

The market is paying $3.03B of equity value, or $2.89B of enterprise value after $134.7M of net cash, for a company with no product revenue and a TTM operating loss of $39.4M; today's 22.98x book is a price for the REGAL/BLA option rather than for current cash flow, and no comparable peer multiple sets a base. The call is PASS: the dated catalysts are real, but they are binary, the equity is priced off book, and cash burn plus continued issuance leave little room for error across the two cases that can actually be priced. The downside is -57.6% to $6.30, taken at a compressed P/B of 12.99x against today's 22.98x. The upside is +30.0% to $19.32, taken at today's P/B of 22.98x. There is no base case: no independent multiple, whether a peer median or the company's own history, was available, and a base at today's multiple is today's price by construction.

Key numbers

  • Share price: $13.66
  • Market cap: $2.78B
  • Latest financial period: TTM to Sep 30, 2026
  • Price / book: 21.12x

The 15 boxes

  1. ✓ 1. Long-form business notes

    The company is a clinical-stage oncology biopharma: the FY2025 10-K lists GPS and SLS009 as product candidates, while the FY2020 10-K listed GPS and NPS and had discontinued GALE-301/GALE-302. Revenue was $1.9M in FY2020, $7.6M in FY2021, $1.0M in FY2022 and $0 in FY2023, and operating income was negative in every year shown through FY2025 and the TTM to Sep 30, 2026. The 3D Medicines Greater China license had produced $10.5M of aggregate upfront and milestone payments as of Dec 31, 2025, and the REGAL trial's final analysis awaited 80 events after 72 events as of Dec 26, 2025.

  2. ✓ 2. Competitive advantage

    None is visible. The company reports no approved products and no product revenue to date, revenue has run from $7.6M in FY2021 to $1.0M in FY2022 to zero in FY2023 with nothing in FY2024, FY2025 or the TTM to Sep 2026, and operating income is negative in every year from FY2020 through FY2025 and -$39.4M in the TTM. Its own 10-K describes only soft advantages (scientific knowledge, development experience) against competitors with substantially greater resources, and the only differentiation claimed is the belief that GPS faces no direct AML maintenance-after-CR2 competition. Scale is 13 full-time employees as of March 1, 2026, and the economics are funded by cash ($134.7M at the TTM date), not by an operating moat.

  3. ✓ 3. 10-Q takeaways

    Q3 2026 was another zero-revenue development quarter: no product sales in the three or nine months to September 30, 2026, total operating expenses of $11.3 million versus $7.1 million in Q3 2025, and an operating loss of $11.3 million versus $7.1 million. Net loss was $10.1 million ($0.05 per share) for the quarter and $28.1 million ($0.15 per share) for the nine months, trimmed only by $1.2 million and $3.1 million of interest income. Cash rose to $134.7 million at September 30, 2026 from $71.8 million at December 31, 2025, funded by $85.1 million of warrant exercises against $22.4 million of nine-month operating cash burn. The outlook is event-based, not numeric: REGAL topline primary endpoint results expected in November 2026 and SLS009 Phase 2 preliminary topline data expected in Q4 2026.

  4. ✓ 4. Corporate governance

    Filled; members read this box.

  5. ✓ 5. Overview of the prior 3 years of 8-K filings

    Filled; members read this box.

  6. ✓ 6. Other significant filings

    Filled; members read this box.

  7. ✓ 7. Chronology of significant news and events

    Filled; members read this box.

  8. ✓ 8. Comparables valuation interpretation

    Filled; members read this box.

  9. ✓ 9. Insider trading interpretation

    Filled; members read this box.

  10. ○ 10. Earnings-call notes
  11. ○ 11. Impression of the shareholder letter
  12. ○ 12. Scuttlebutt overview
  13. ✓ 13. Valuation and risk/reward summary

    Filled; members read this box.

  14. ✓ 14. Current price suppression and potential catalysts

    Filled; members read this box.

  15. ✓ 15. Conclusions

    The call above.

Sign in with a QuantSignals Premium or Gold plan to read every box: each point linked to the SEC filing it came from, the bull and bear case, and the comparables. QS Research powers the signals behind FST, our autonomous trading agent.

Put these signals to work

The Scion template's preview is free. Paid members read every box of every report. FST, the QuantSignals trading agent, uses QS Research as its brain.

Join freeMeet FSTSee plans